#1 Clinical Trials Search in Europe

Navtemadlin

This article examines the use of Navtemadlin, an experimental MDM2 inhibitor anticancer drug, in various clinical trials. Navtemadlin is being studied for its potential in treating different types of cancer, including endometrial cancer, non-small cell lung cancer, myelofibrosis, leukemia, soft tissue sarcoma, and multiple myeloma. The trials aim to evaluate its safety, efficacy, and optimal dosing when used alone or in combination with other treatments.

Table of Contents

What is Navtemadlin?

Navtemadlin, also known as KRT-232 or AMG 232, is an experimental cancer drug that is currently being studied in clinical trials[1][2]. It is a type of medication called an MDM2 inhibitor, which means it works by blocking a protein in the body called MDM2[3]. This protein is important for cancer cell growth, so by blocking it, navtemadlin may be able to stop or slow down the growth of cancer cells.

How Does Navtemadlin Work?

Navtemadlin works by targeting a specific protein in cancer cells called MDM2. This protein is often overactive in cancer cells and helps them grow and survive. By blocking MDM2, navtemadlin may be able to:

  • Stop cancer cells from growing and dividing
  • Cause cancer cells to die
  • Make cancer cells more sensitive to other cancer treatments
Researchers believe that by interfering with MDM2, navtemadlin can help activate a natural cancer-fighting protein in our bodies called p53[4]. The p53 protein is often referred to as the “guardian of the genome” because it helps prevent damaged cells from turning into cancer cells.

What Cancers Does Navtemadlin Treat?

Navtemadlin is being studied in clinical trials for several types of cancer, including:

  • Endometrial cancer: Cancer of the lining of the uterus[1]
  • Non-small cell lung cancer: A common type of lung cancer[2]
  • Myelofibrosis: A rare type of blood cancer that affects bone marrow[5]
  • Acute myeloid leukemia (AML): A type of blood and bone marrow cancer[6]
  • Glioblastoma: An aggressive type of brain cancer[7]
  • Multiple myeloma: A cancer of plasma cells in the bone marrow[8]
  • Soft tissue sarcoma: Cancers that develop in soft tissues like muscles and fat[4]
It’s important to note that navtemadlin is still experimental and not yet approved for general use. Its effectiveness in treating these cancers is still being studied.

How is Navtemadlin Given?

Navtemadlin is typically given as an oral medication, which means it’s taken by mouth as a pill or capsule[1][2]. In most clinical trials, it’s given once daily for a certain number of days in each treatment cycle. For example:

  • In some trials, it’s given for 7 days out of a 28-day cycle[1]
  • In others, it’s given for 7 days out of a 21-day cycle[2]
The exact dosing schedule can vary depending on the type of cancer being treated and whether navtemadlin is being given alone or in combination with other treatments.

Navtemadlin is being studied in various clinical trials, which are research studies that test how well new medical approaches work in people. These trials are looking at navtemadlin in different ways:

  • As a single agent: Some trials are testing navtemadlin on its own to see how effective it is[1]
  • In combination with other treatments: Other trials are testing navtemadlin together with standard cancer treatments like chemotherapy or radiation therapy[2][4]
  • As a maintenance therapy: Some studies are looking at using navtemadlin to help keep cancer from coming back after other treatments[1]
These clinical trials are helping researchers understand how well navtemadlin works, what dose is best, and what side effects it might cause.

Potential Side Effects

As with all medications, navtemadlin can potentially cause side effects. Since it’s still in clinical trials, researchers are carefully monitoring patients to understand what these side effects might be. Some potential side effects that are being watched for include:

  • Changes in blood cell counts
  • Fatigue
  • Nausea or vomiting
  • Diarrhea
  • Loss of appetite
It’s important to remember that not everyone experiences side effects, and the severity can vary from person to person. In clinical trials, doctors closely monitor patients for any side effects and adjust treatment as needed[3].

Future of Navtemadlin

Navtemadlin is still in the early stages of research, but it shows promise in treating several types of cancer. Researchers are excited about its potential because:

  • It targets a specific protein (MDM2) that helps cancer cells grow
  • It may be effective against cancers that are resistant to other treatments
  • It can be taken orally, which is often more convenient for patients
However, more research is needed to fully understand how effective navtemadlin is and whether it’s safe for long-term use. The ongoing clinical trials will help answer these questions and determine if navtemadlin could become a new treatment option for cancer patients in the future[1][2][5].

Aspect Details
Drug Name Navtemadlin (also known as KRT-232, AMG 232)
Drug Class MDM2 inhibitor
Administration Oral (by mouth)
Cancer Types Studied Endometrial cancer, non-small cell lung cancer, myelofibrosis, acute myeloid leukemia, soft tissue sarcoma, glioblastoma, multiple myeloma
Trial Phases Phase 0/I, I, Ib, II, II/III, III
Study Objectives Safety, tolerability, optimal dosing, efficacy, pharmacokinetics, pharmacodynamics
Combination Therapies Chemotherapy drugs (e.g., cytarabine, idarubicin), targeted therapies (e.g., venetoclax), radiation therapy
Key Outcome Measures Maximum tolerated dose, recommended phase 2 dose, progression-free survival, overall response rate, adverse events

FAQ

  • What is Navtemadlin? Navtemadlin is an experimental MDM2 inhibitor anticancer drug taken by mouth. It works by blocking some of the enzymes needed for cancer cell growth, potentially stopping or slowing the growth of cancer cells.
  • What types of cancer is Navtemadlin being studied for? Navtemadlin is being studied in clinical trials for various types of cancer, including endometrial cancer, non-small cell lung cancer, myelofibrosis, acute myeloid leukemia, soft tissue sarcoma, glioblastoma, and multiple myeloma.
  • How is Navtemadlin administered? Navtemadlin is typically administered orally (by mouth) once daily, often for 7 days in a 21- or 28-day treatment cycle. The exact dosing schedule may vary depending on the specific trial and cancer type being studied.
  • Is Navtemadlin used alone or in combination with other treatments? Navtemadlin is being studied both as a single agent and in combination with other treatments. Some trials are investigating its use with standard chemotherapy drugs, targeted therapies, or radiation therapy to potentially enhance their effectiveness.
  • What are the main goals of the Navtemadlin clinical trials? The main goals of the Navtemadlin clinical trials include evaluating its safety and tolerability, determining the optimal dose, assessing its efficacy in treating various cancers, and studying its pharmacokinetics and pharmacodynamics when used alone or in combination with other treatments.

Ongoing Clinical Trials on Navtemadlin

  • Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Croatia Czechia France Germany +7

  • Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy

  • Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Czechia France Germany Greece +7

  • Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Czechia Denmark Estonia Finland France +9

Glossary

  • MDM2 inhibitor: A type of drug that blocks the MDM2 protein, which is involved in cancer cell growth and survival. By inhibiting MDM2, these drugs may help stop or slow the growth of cancer cells.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. PK profiles help determine the optimal dosing and administration of a drug.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of a drug on the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects. This is often determined in phase I clinical trials.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug recommended for further testing in phase II clinical trials, based on safety and efficacy data from phase I trials.
  • Dose-Limiting Toxicity (DLT): A side effect that is severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment.
  • Partial Response (PR): A decrease in the size of a tumor or in the extent of cancer in the body in response to treatment.

References

  1. https://clinicaltrials.gov/study/NCT05797831
  2. https://clinicaltrials.gov/study/NCT05705466
  3. https://clinicaltrials.gov/study/NCT03041688
  4. https://clinicaltrials.gov/study/NCT03217266
  5. https://clinicaltrials.gov/study/NCT06479135
  6. https://clinicaltrials.gov/study/NCT04190550
  7. https://clinicaltrials.gov/study/NCT03107780
  8. https://clinicaltrials.gov/study/NCT03031730